{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:19:08Z","timestamp":1790705948705,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007290","name":"Det Obelske Familiefond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.amjmed.2018.01.041","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T04:56:29Z","timestamp":1519188989000},"page":"787-794.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism"],"prefix":"10.1016","volume":"131","author":[{"given":"Mette","family":"S\u00f8gaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Br\u00f8nnum","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Skj\u00f8th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette Nordstr\u00f8m","family":"Kj\u00e6ldgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Bjerregaard","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.amjmed.2018.01.041_bib0010","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American heart association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjmed.2018.01.041_bib0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11239-009-0309-3","article-title":"Incidence and cost burden of post-thrombotic syndrome","volume":"28","author":"Ashrani","year":"2009","journal-title":"J Thromb Thrombolysis"},{"issue":"20 suppl","key":"10.1016\/j.amjmed.2018.01.041_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2146\/ajhp060388","article-title":"Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome","volume":"63","author":"MacDougall","year":"2006","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"10.1016\/j.amjmed.2018.01.041_bib0025","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/jth.13741","article-title":"Chronic complications of venous thromboembolism","volume":"15","author":"Winter","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.amjmed.2018.01.041_bib0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/jth.13569","article-title":"The postthrombotic syndrome: current evidence and future challenges","volume":"15","author":"Rabinovich","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.amjmed.2018.01.041_bib0035","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1538-7836.2012.04872.x","article-title":"Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study","volume":"10","author":"Chitsike","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.amjmed.2018.01.041_bib0040","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1538-7836.2005.01333.x","article-title":"Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome","volume":"3","author":"van Dongen","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.amjmed.2018.01.041_bib0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.thromres.2014.05.035","article-title":"Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients","volume":"134","author":"Mearns","year":"2014","journal-title":"Thromb Res"},{"issue":"26","key":"10.1016\/j.amjmed.2018.01.041_bib0050","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.amjmed.2018.01.041_bib0055","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2018.01.041_bib0060","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"Ageno","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.amjmed.2018.01.041_bib0065","first-page":"472","article-title":"Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)","volume":"116","author":"Kucher","year":"2016","journal-title":"Thromb Haemost"},{"issue":"17","key":"10.1016\/j.amjmed.2018.01.041_bib0070","first-page":"1","article-title":"Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study","volume":"13","author":"Larsen","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.amjmed.2018.01.041_bib0075","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1160\/TH17-03-0210","article-title":"Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism","volume":"117","author":"Coleman","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2018.01.041_bib0080","first-page":"219","article-title":"Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep vein thrombosis","volume":"13","author":"Cheung","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2018.01.041_bib0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2017.05.029","article-title":"Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome","volume":"157","author":"Jeraj","year":"2017","journal-title":"Thrombosis Research"},{"issue":"supplS1","key":"10.1016\/j.amjmed.2018.01.041_bib0090","first-page":"948","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism","volume":"1","author":"Coleman","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.amjmed.2018.01.041_bib0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jclinepi.2009.03.018","article-title":"Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution","volume":"63","author":"Severinsen","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.amjmed.2018.01.041_bib0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"5","key":"10.1016\/j.amjmed.2018.01.041_bib0105","first-page":"363","article-title":"All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries","volume":"18","author":"Lefebvre","year":"2012","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"10.1016\/j.amjmed.2018.01.041_bib0110","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1160\/TH13-05-0425","article-title":"All-cause and disease-related health care costs associated with recurrent venous thromboembolism","volume":"110","author":"Lefebvre","year":"2013","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.amjmed.2018.01.041_bib0115","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjmed.2018.01.041_bib0120","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.amjmed.2018.01.041_bib0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2018.01.041_bib0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"issue":"28","key":"10.1016\/j.amjmed.2018.01.041_bib0135","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.amjmed.2018.01.041_bib0140","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.amjmed.2018.01.041_bib0145","doi-asserted-by":"crossref","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.amjmed.2018.01.041_bib0150","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/jth.12604","article-title":"Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study","volume":"12","author":"Schmidt","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2018.01.041_bib0155","article-title":"Diagnostic scales for the post-thrombotic syndrome","author":"Wik","year":"2017","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.amjmed.2018.01.041_bib0160","first-page":"252","article-title":"The quality of routine oral anticoagulant therapy in a large geographical area. a survey of 310,300 inhabitants","volume":"49","author":"Holm","year":"2002","journal-title":"Dan Med Bull"},{"issue":"13","key":"10.1016\/j.amjmed.2018.01.041_bib0165","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.113.002601","article-title":"National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation","volume":"129","author":"Dlott","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjmed.2018.01.041_bib0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.amjmed.2018.01.041_bib0180","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-149-10-200811180-00004","article-title":"Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis","volume":"149","author":"Kahn","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.amjmed.2018.01.041_bib0185","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.amjmed.2018.01.041_bib0190","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1538-7836.2012.04806.x","article-title":"Prevention of post-thrombotic syndrome: a case for new oral anticoagulant drugs or for heparins?","volume":"10","author":"Baglin","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.amjmed.2018.01.041_bib0195","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2012.04798.x","article-title":"Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome","volume":"10","author":"Bouman","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2018.01.041_bib0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","article-title":"Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran","volume":"142","author":"Ellinghaus","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.amjmed.2018.01.041_bib0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2016.06.008","article-title":"Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis","volume":"144","author":"Terry","year":"2017","journal-title":"Thromb Res"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318301189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318301189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:13:56Z","timestamp":1757582036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934318301189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0002934318301189"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.01.041","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}